



(51) International Patent Classification:

A61M 5/148 (2006.01) A61M 5/142 (2006.01)

(21) International Application Number:

PCT/EP2018/051375

(22) International Filing Date:

22 January 2018 (22.01.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17152921.7 24 January 2017 (24.01.2017) EP

(71) Applicant: **SANOFI-AVENTIS DEUTSCHLAND GMBH** [DE/DE]; Brünningstraße 50, 65929 Frankfurt am Main (DE).

(72) Inventors: **VERLAAK, Stefan**; c/o FLEXTRONICS DESIGN SRL, Via Ernesto Breda 176, 20126 Milano (MI) (IT). **MELZI, Ilario**; c/o FLEXTRONICS DESIGN SRL, Via Ernesto Breda 176, 20126 Milano (MI) (IT).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MEDICAMENT DELIVERY DEVICE

10




Figure 1

(57) Abstract: A medicament delivery device for delivering a liquid medicament comprising: a rigid casing containing a deformable medicament container, the deformable medicament container arranged to contain the liquid medicament; a pressurized gas cartridge connected to the rigid casing via a gas valve; wherein the gas valve is releasable to allow gas flow into the rigid casing to cause an increase in gas pressure in the rigid casing so as to compress the deformable medicament container to displace the liquid medicament.



**Declarations under Rule 4.17:**

— *of inventorship (Rule 4.17(iv))*

**Published:**

— *with international search report (Art. 21(3))*

## **Medicament Delivery Device**

### **Field**

The present invention relates to a device for delivery of medicament to a patient.

### **Background of the Invention**

A variety of diseases exist that require regular treatment by injection of a medicament and such injections can be performed by using injection devices. Various injection devices for delivering injections of medicament are known in the art. Another type of injection pump that is gaining traction is the bolus injector device. Some bolus injector devices are intended to be used with relatively large volumes of medicament, typically at least 1 ml and maybe a few ml. Injection of such large volumes of medicament can take some minutes or even hours. Such high capacity bolus injector devices can be called large volume devices (LVDs). Generally such devices are operated by the patients themselves, although they may also be operated by medical personnel.

To use an injector device, such as an LVD, it is first supported on a suitable injection site on a patient's skin. Once installed, injection is initiated by the patient or another person (user). Typically, the initiation is effected by the user operating an electrical switch, which causes a controller to operate the device. Operation includes firstly injecting a needle into the user and then causing the injection of medicament into the user's tissue. Biological medicaments are being increasingly developed which comprise higher viscosity injectable liquids and which are to be administered in larger volumes than long-known liquid medicaments. LVDs for administering such biological medicaments may comprise a pre-filled disposable drug delivery device or, alternatively, a disposable drug delivery device into which a patient or medical personnel must insert a drug cartridge prior to use.

Some medicament delivery devices use bungs and plungers for advancing the liquid medicament during an injection process, but these bungs and plungers may introduce inefficiency during injection due to friction. Furthermore, in these injection arrangements with bungs and plungers, there may be dead volume within medicament

containers or syringes due to manufacturing tolerances, which may lead to residual drug even with after fully advancing the bung.

In some patient-operated LVDs, the drug delivery process from start to finish may be a lengthy process and sometimes it is difficult for the patient to determine whether the injection process is complete. Some medicament delivery devices are provided with on-board equipment including light sources and indicator systems for indicating the amount of medicament currently contained within the device. In some of these devices with on-board equipment, batteries are provided so as to power the on-board equipment. However, these devices are often stored for a relatively long time before being used for delivering medicament. A problem is that, during this time of storage, battery corrosion and leakage may occur.

### **Summary of the Invention**

According to an aspect of the present invention, there is provided a medicament delivery device for delivering a liquid medicament comprising: a rigid casing containing a deformable medicament container, the deformable medicament container arranged to contain the liquid medicament; a pressurized gas cartridge connected to the rigid casing via a gas valve; wherein the gas valve is releasable to allow gas flow into the rigid casing to cause an increase in gas pressure in the rigid casing so as to compress the deformable medicament container to displace the liquid medicament.

The medicament delivery device may further comprising an overflow reservoir connected to the rigid casing via a safety valve, wherein the safety valve is configured to allow gas flow into the overflow reservoir when gas pressure in the rigid casing exceed a predetermined threshold.

The medicament delivery device may further comprise a flow detection mechanism in the overflow reservoir.

The flow detection mechanism may comprise a rotation member arranged in the overflow reservoir, wherein the rotation member is configured to be rotated by gas flow in the overflow reservoir.

The rotation member may comprise a plurality of vanes.

The rotation member may be connected to an indicator system.

The indicator system may comprise: a transparent window at the housing; and an indicator member arranged at the rotation member, such that when the rotation member rotates, an outer end of the indicator member moves along the transparent window.

The rotation member may be connected to an energy generating apparatus.

The energy generating apparatus may comprise a dynamo.

The medicament delivery device may further comprise a light source arranged to be powered by the energy generating apparatus.

The deformable medicament container may be in fluid communication with an outlet, the outlet being connected via a fluid path to a needle injection system.

The medicament delivery device may be a bolus injector.

The deformable medicament container may contain a liquid medicament.

According to another aspect of the present invention, there is provided a method of operating a medical delivery device, the medical delivery device comprising a rigid casing containing a deformable medicament container arranged to contain a liquid medicament and a pressurized gas cartridge connected to the rigid casing via a gas valve, the method comprising: releasing the gas valve to allow gas flow into the rigid casing to cause an increase in gas pressure in the rigid casing so as to compress the deformable medicament container to displace the liquid medicament.

The medical delivery device may further comprise an overflow reservoir connected to the rigid casing via a safety valve, and the method may further comprise converting motion of gas flow in the overflow reservoir into torque for rotating a rotation member in the overflow reservoir.

These and other aspects of the invention will be apparent from and elucidated with reference to the embodiments described hereinafter.

### **Brief Description of the Drawings**

Exemplary embodiments of the present invention are described with reference to the accompanying drawings, in which:

Figure 1 is a schematic view of a medicament delivery device in an initial state, according to a first embodiment;

Figure 2 is a schematic view of a medicament delivery device in a final state, according to the first embodiment;

Figure 3A is a schematic view of part of the medicament delivery device in a first state, according to a second embodiment;

Figure 3B is a schematic view of part of the medicament delivery device in a second state, according to the second embodiment; and

Figure 4 is a schematic view of a medicament delivery device according to a third embodiment.

Reference will now be made in detail to the embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout.

### **Details Description of the Embodiments**

A medicament delivery device for delivering a liquid medicament is provided. The medicament delivery device comprises a rigid casing containing a deformable medicament container, the deformable medicament container arranged to contain the liquid medicament; a pressurized gas cartridge connected to the rigid casing via a gas valve; wherein the gas valve is releasable to allow gas flow into the rigid casing to cause an increase in gas pressure in the rigid casing so as to compress the deformable medicament container to displace the liquid medicament.

The medicament delivery device as described avoids the friction associated with bungs and plungers. Furthermore, the dead volume is considerably smaller since the volume inside the deformable medicament container can virtually be reduced to zero whereas

in conventional injection arrangements there is usually some residual drug even with after fully advancing the bung due to manufacturing tolerances.

A drug delivery device, as described herein, may be configured to inject a medicament into a patient. For example, delivery could be sub-cutaneous, intra-muscular, or intravenous. Such a device could be operated by a patient or care-giver, such as a nurse or physician, and can include various types of safety syringe, pen-injector, or auto-injector. The device can include a cartridge-based system that requires piercing a sealed ampule before use. Volumes of medicament delivered with these various devices can range from about 0.5 ml to about 2 ml. Yet another device can include a large volume device ("LVD") or patch pump, configured to adhere to a patient's skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a "large" volume of medicament (typically about 2 ml to about 10 ml).

In combination with a specific medicament, the presently described devices may also be customized in order to operate within required specifications. For example, the device may be customized to inject a medicament within a certain time period (e.g., about 3 to about 20 seconds for auto-injectors, and about 10 minutes to about 60 minutes for an LVD). Other specifications can include a low or minimal level of discomfort, or to certain conditions related to human factors, shelf-life, expiry, biocompatibility, environmental considerations, etc. Such variations can arise due to various factors, such as, for example, a drug ranging in viscosity from about 3 cP to about 50 cP. Consequently, a drug delivery device will often include a hollow needle ranging from about 25 to about 31 Gauge in size. Common sizes are 27 and 29 Gauge.

The delivery devices described herein can also include one or more automated functions. For example, one or more of needle insertion, medicament injection, and needle retraction can be automated. Energy for one or more automation steps can be provided by one or more energy sources. Energy sources can include, for example, mechanical, pneumatic, chemical, or electrical energy. For example, mechanical energy sources can include springs, levers, elastomers, or other mechanical mechanisms to store or release energy. One or more energy sources can be combined into a single device. Devices can further include gears, valves, or other mechanisms to convert energy into movement of one or more components of a device.

Some delivery devices can include one or more functions of a safety syringe, pen-injector, or auto-injector. For example, a delivery device could include a mechanical energy source configured to automatically inject a medicament (as typically found in an auto-injector) and a dose setting mechanism (as typically found in a pen-injector).

Figure 1 is a schematic view of a medicament delivery device in an initial state, according to a first embodiment. The device is described below in the context of a Large Volume Device (LVD), but it will be appreciated that it could alternatively be another type of bolus injector.

A medicament delivery device 10 according to a first embodiment of the invention is shown in Figure 1. The medicament delivery device 10 can either be a stationary or a portable device. The medicament delivery device 10 comprises a housing 11 containing a rigid casing 12 connected to a pressurized gas cartridge 14 via a gas valve 15. The rigid casing 12 may be made of metal or hard plastic, and it will be appreciated that the rigid casing may be made of other materials that provide the required rigidity of the rigid casing 12.

The pressurized gas cartridge 14 in this embodiment has a volume of 5ml and contains nitrogen gas pressurized at 1,000Pa. The gas valve 15 in the present embodiment is controlled by an actuator (not shown in Figure 1). When the actuator is actuated, the gas valve 15 is arranged to release to as to allow gas flow from the pressurized gas cartridge 14 into the rigid casing 12. In this embodiment, the gas valve 15 is a one-way valve that only allows gas to flow through in one direction, i.e. from the pressurized gas cartridge 14 to the rigid casing 12.

The rigid casing 12 contains a deformable medicament container 13 which in the initial state is filled with liquid medicament. The deformable medicament container 13 may be made of plastic, e.g. polyvinyl chloride (PVC) or polyethylene. In the present embodiment, the deformable medicament container 13 is attached at a side of the rigid casing 12 opposite the outlet of the medicament container 13, in order to ensure a precise folding of the deformable medicament container 13. Specifically, as shown in this embodiment, the rigid casing 12 has an elongate shape and the deformable medicament container 13 is held at a front end in the region of the outlet of the

medicament container 13 where it is sealed against the rigid casing 12 and at a back end opposite the outlet of the medicament container 13. In the initial state, the deformable medicament container 13 with the liquid medicament essentially fills the entire volume of the rigid casing 12.

The deformable medicament container 13 comprises an outlet through which medicament can be displaced. The outlet of the deformable medicament container 13 is connected to a needle injection system 19 through a fluid path 18. In other words, an end of the fluid path 18 is connected to the outlet of the medicament container 13 while another end of the fluid path 18 is connected to a needle injection system 19. The needle injection system 19 includes a hollow injection needle 21 through which medicament can be displaced when the deformable medicament container 13 is compressed.

The rigid casing 12 is fillable by gas for displacing the deformable medicament container 13 and thus the liquid medicament inside. Therefore, when the gas valve 15 releases to allow gas flow into the rigid casing 12, the increase gas pressure exerts a compressive force on the deformable medicament container 13 so as to displace the liquid medicament contained within through its outlet.

The medicament delivery device 10 further comprises an overflow reservoir 16. The overflow reservoir 16 is connected to the rigid casing 12 via a safety valve 17. The safety valve 17 is configured such that when a gas pressure within the rigid casing 12 exceeds a predetermined threshold, the safety valve 17 releases so as to allow gas flow into the overflow reservoir. Hence, safety can be ensured by preventing a scenario in which the gas pressure within the rigid casing reaches dangerously high levels. In this embodiment, the safety valve 17 is a pressure relief valve (PRV) which is set to open at a predetermined set pressure to protect the rigid casing 12 from being subjected to pressures that exceed its design limit.

Figure 2 is a schematic view of a medicament delivery device in a final state, according to the first embodiment.

The medicament delivery device 10 as shown in Figure 2 is in the final state, when the actuator which is arranged to control the gas valve 15 is actuated to allow gas flow

from the pressurized gas cartridge 14 in the rigid casing 12. In the final state, the whole content of the deformable medicament container 13 may be forced out of the outlet by entirely filling the rigid casing 12 with gas and thereby fully compressing the deformable medicament container 13.

Due to the rigidity of the rigid casing 12, when gas flows into the rigid casing 12 from the pressurized gas cartridge 14, the increased gas pressure exerts a compressive force on the deformable medicament container 13 arranged within the rigid casing 12 to compress the deformable medicament container 13. The liquid medicament contained within the deformable medicament container 13 is displaced through its outlet, through the fluid path, and to the needle injection system 19 to be injected to an injection site.

Once all the content within the deformable medicament container 13 has been displaced, the gas pressure within the rigid casing 12 will continue to increase due to the continued gas flow from the pressurized gas cartridge 14. When the gas pressure within the rigid casing exceeds the predetermined threshold, the safety valve 17 would release to allow gas flow into the overflow reservoir 16. This gas flow from the rigid casing 12 causes the gas pressure in the rigid casing 12 to decrease and therefore damage to the rigid casing 12 due to high gas pressure can be prevented.

Figure 3A is a schematic view of part of a medicament delivery device in a first state, according to a second embodiment, and Figure 3B is a schematic view of part of the medicament delivery device in a second state, according to the second embodiment. Specifically, Figures 3A and 3B show part of the overflow reservoir 26 of the medicament delivery device respectively before completion of the injection process (i.e. the first state), and after completion of the injection process (i.e. the second state).

The medicament delivery device of the second embodiment is similar to the medicament delivery device 10 of the first embodiment, with the addition of a rotation member 22 arranged in the overflow reservoir 16, the rotation member 22 being connected to an indicator system comprising an indicator member 23 and a transparent window 24. The transparent window 24 in this embodiment is positioned at the housing 11 to allow a user to determine an orientation of the indicator member.

In this embodiment, the rotation member 22 is considered as a flow detection mechanism. The rotation member 22 is arranged in the overflow reservoir 16 and is in particular configured to rotate in a single direction (clockwise as shown in Figures 3A and 3B) when gas flows into the overflow reservoir 16 from the rigid casing 12. In other words, motion of gas flow in the overflow reservoir 16 is converted into torque for rotating the rotation member 22.

In this embodiment, the indicator member 23 of the indicator system is a narrow elongate member arranged at a surface of the rotation member 22 such that it extends from a center of the rotation member 22 outwards. The indicator member 23 is fixedly attached to the rotation member 22 such that as the rotation member 22 rotates, an outer end of the indicator member 23 moves along the transparent window 24 from a first position to a second position. The first position corresponds to the first state in which the injection process is not complete, and the second position corresponds to the second state in which the injection process is complete.

A first end of the transparent window 24 represents when the deformable medicament container 13 is non-empty, and a second end of the transparent window 24 represents when the deformable medicament container 13 is empty. Therefore, when the outer end of the indicator member 23 moves along the transparent window 24 from one end to another, a user is able to determine that the injection process is complete.

When the actuator (not shown in the drawing) is actuated to release the gas valve 15, the rigid casing 12 is gradually filled with gas and thus the gas pressure within the rigid casing 12 continues to increase. This increasing gas pressure exerts a compressive force on the deformable medicament container 13 so as to displace the liquid medicament contained within through its outlet.

Once all the content within the deformable medicament container 13 has been displaced, the gas pressure within the rigid casing 12 will continue to increase due to the continued gas flow from the pressurized gas cartridge 14. When the gas pressure within the rigid casing exceeds the predetermined threshold, the safety valve 17 would release to allow gas flow into the overflow reservoir 16.

The gas flow into the overflow reservoir 16 causes a rotation of the rotation member 22 in a single direction, which in turn causes the outer end of the indicator member 23 to sweep along the transparent window 24 from one end to another. This is illustrated in Figure 3A and Figure 3B, which respectively show the outer end of the indicator member 23 in the first position (Figure 3A) and in the second position (Figure 3B). Hence, when the outer end of the indicator member 23 moves from one end to another along the transparent window 24, the user is able to determine when the deformable medicament container 13 is empty and when the injection process is complete by checking the orientation of the indicator member 23.

Figure 4 is a schematic view of part of a medicament delivery device according to a third embodiment.

The medicament delivery device of the third embodiment is similar to the medicament delivery device the first embodiment, with the addition of a rotation member 22, a pinion gear (not shown in Figure 4), a worm wheel 25, a worm screw 26, an energy generating apparatus 27, and a light source 28.

In this embodiment, the rotation member 22 is considered as part of a flow detection mechanism. The rotation member 22 is arranged in the overflow reservoir 16 and is in particular configured to rotate in a single when gas flows into the overflow reservoir 16 from the rigid casing 12. In other words, motion of gas flow in the overflow reservoir 16 is converted into torque for rotating the rotation member 22.

As shown in Figure 4, in this embodiment the rotation member 22 comprises a plurality of vanes and is fixedly attached to a pinion gear (not shown in Figure 4) configured to mesh with the worm wheel 25. The worm wheel 25 in this embodiment forms a worm drive arrangement with a worm screw 26. Specifically, the worm wheel 25 comprises a plurality of teeth which mesh with a threaded arrangement on an outer surface of the worm screw 26. In this worm drive arrangement, rotary motion is transmitted through a 90° angle. In other words, the rotary motion of the worm wheel 25 in a first axis causes a rotary motion of the worm screw 26 in a second axis, the first axis being perpendicular to the second axis.

The worm screw 26 is mechanically connected to the energy generating apparatus 27. In this embodiment, the energy generating apparatus 27 comprises a dynamo which is configured to convert mechanical rotation into a direct electric current.

Although not shown in the drawing, the energy generating apparatus 27 is electrically connected to a light source 28, which in this embodiment is a light bulb. Therefore, as energy generating apparatus 27 converts mechanical rotation of the worm screw 26, the light source 28 is powered.

When the actuator (not shown in the drawing) is actuated to release the gas valve 15, the rigid casing 12 is gradually filled with gas and thus the gas pressure within the rigid casing 12 continues to increase. This increasing gas pressure exerts a compressive force on the deformable medicament container 13 so as to displace the liquid medicament contained within through its outlet.

Once all the content within the deformable medicament container 13 has been displaced, the gas pressure within the rigid casing 12 will continue to increase due to the continued gas flow from the pressurized gas cartridge 14. When the gas pressure within the rigid casing exceeds the predetermined threshold, the safety valve 17 would release to allow gas flow into the overflow reservoir 16.

The gas flow into the overflow reservoir 16 causes a rotation of the rotation member 22 in a single direction. Due to the attachment between the rotation member 22 and the pinion gear (not shown in Figure 4), the pinion gear rotates together with the rotation member 22 and meshes with the worm wheel 25 which in turn meshes with the worm screw 26 so as to transmit rotary motion through a 90° angle. As the worm screw 26 rotates, a current is generated by the energy generating apparatus 27 to which the worm screw 26 is connected to. In the present embodiment, this generated energy is used to power the light source 31. Thus, the light source 31 can be used for indicating that the injection process is complete.

In alternative embodiments, the medicament delivery device may be a pen injector instead of a bolus injector.

In alternative embodiments, the energy generating apparatus may be electrically connected to an energy storing apparatus, such as a capacitor, instead of being connected directly to a light source. In these alternative embodiments, the energy (direct electric current) generated at the energy generating apparatus may be stored at the energy storing apparatus and may be used subsequently for powering on-board equipment at the device.

In alternative embodiments, the deformable medicament container may be made of other material which would allow the medicament container to be compressed and/or folded under gas pressure.

In alternative embodiments, the gas valve at which the pressurized gas cartridge and the rigid casing are connected may be controllable by a different element in the device. For example, the gas valve may be controlled by a control device (e.g. a dial) so as to control and adjust a gas flow rate from the pressurized gas cartridge into the rigid casing. Also, in alternative embodiments, other types of valves (e.g. a diaphragm valve, a pinch valve, etc.) may be used instead of a one-way valve as the gas valve.

In alternative embodiments, other types of gases (e.g. air, carbon dioxide, oxygen, etc.) may be used as the gas contained in the pressurized gas cartridge, instead of nitrogen. Also, in alternative embodiments, the gas contained in the pressurized gas cartridge may be pressurized in a different gas pressure value.

In alternative embodiments, the size and/or dimension of the pressurized gas cartridge may be adapted according to design requirements.

In alternative embodiments, the safety valve at which the overflow reservoir and the rigid casing are connected may be a pressure safety valve (PSV) instead of a pressure relief valve (PRV). Also, in alternative embodiments, other types of valves may be used as the safety valve, instead of a pressure relief valve.

In alternative embodiments, the rotation member may be replaced by other types of flow detection mechanisms in the overflow reservoir. In these alternative embodiments, the flow detection mechanism may comprise at least one of a: an Archimedes screw member, an ultrasonic detection device, an electromagnetic transmission detection

device. Also, in these alternative embodiments, the flow detection mechanism may be connected to the indicator system or the energy generating apparatus. For example, in an alternative embodiment with a flow detection mechanism comprising an Archimedes screw member, the Archimedes screw member may be mechanically connected to an energy generating apparatus so as to generate direct current when the Archimedes screw member rotates due to gas flow in the overflow reservoir.

In alternative embodiments, the indicator member and the scale of the indicator system may adopt other shapes and configurations. For example, the indicator member in an alternative embodiment may be a fan-shaped member arranged at a surface of the rotation member such that it extends from a center of the rotation member outwards, and the scale may be an arc-shaped aperture of a flat covering member arranged on top of the indicator member. The indicator member may be fixedly attached to the rotation member such that as the rotation member rotates, the indicator member rotates so as to cover the arc-shaped aperture (i.e. the scale). In other alternative embodiments, a linear scale may be used instead.

Although claims have been formulated in this application to particular combinations of features, it should be understood that the scope of the disclosure also includes any novel features or any novel combinations of features disclosed herein either explicitly or implicitly or any generalization thereof, whether or not it relates to the same invention as presently claimed in any claim and whether or not it mitigates any or all of the same technical problems as does the present invention. The applicant hereby gives notice that new claims may be formulated to such features and/or combinations of features during the prosecution of the present application or of any further application derived therefrom.

Those skilled in the art will understand that modifications (additions and/or removals) of various components of the substances, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope and spirit of the present invention, which encompass such modifications and any and all equivalents thereof.

The terms "drug" or "medicament" are used synonymously herein and describe a pharmaceutical formulation containing one or more active pharmaceutical ingredients

or pharmaceutically acceptable salts or solvates thereof, and optionally a pharmaceutically acceptable carrier. An active pharmaceutical ingredient ("API"), in the broadest terms, is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. A drug or medicament may be used for a limited duration, or on a regular basis for chronic disorders.

As described below, a drug or medicament can include at least one API, or combinations thereof, in various types of formulations, for the treatment of one or more diseases. Examples of API may include small molecules having a molecular weight of 500 Da or less; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.

The term "drug delivery device" shall encompass any type of device or system configured to dispense a drug or medicament into a human or animal body. Without limitation, a drug delivery device may be an injection device (e.g., syringe, pen injector, auto injector, large-volume device, pump, perfusion system, or other device configured for intraocular, subcutaneous, intramuscular, or intravascular delivery), skin patch (e.g., osmotic, chemical, micro-needle), inhaler (e.g., nasal or pulmonary), an implantable device (e.g., drug- or API-coated stent, capsule), or a feeding system for the gastrointestinal tract. The presently described drugs may be particularly useful with injection devices that include a needle, e.g., a hypodermic needle for example having a Gauge number of 24 or higher.

The drug or medicament may be contained in a primary package or "drug container" adapted for use with a drug delivery device. The drug container may be, e.g., a cartridge, syringe, reservoir, or other solid or flexible vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more drugs. For example, in some instances, the chamber may be designed to store a drug for at

least one day (e.g., 1 to at least 30 days). In some instances, the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20°C), or refrigerated temperatures (e.g., from about -4°C to about 4°C). In some instances, the drug container may be or may include a dual-chamber cartridge configured to store two or more components of the pharmaceutical formulation to-be-administered (e.g., an API and a diluent, or two different drugs) separately, one in each chamber. In such instances, the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and/or during dispensing into the human or animal body. For example, the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing. Alternatively or in addition, the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.

The drugs or medicaments contained in the drug delivery devices as described herein can be used for the treatment and/or prophylaxis of many different types of medical disorders. Examples of disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism. Further examples of disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis. Examples of APIs and drugs are those as described in handbooks such as Rote Liste 2014, for example, without limitation, main groups 12 (anti-diabetic drugs) or 86 (oncology drugs), and Merck Index, 15th edition.

Examples of APIs for the treatment and/or prophylaxis of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, e.g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof. As used herein, the terms "analogue" and "derivative" refer to any substance which is sufficiently structurally similar to the original substance so as to have substantially similar functionality or activity (e.g., therapeutic effectiveness). In particular, the term "analogue" refers to a

polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring peptide and/or by adding at least one amino acid residue. The added and/or exchanged amino acid residue can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. Insulin analogues are also referred to as "insulin receptor ligands". In particular, the term "derivative" refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, in which one or more organic substituent (e.g. a fatty acid) is bound to one or more of the amino acids. Optionally, one or more amino acids occurring in the naturally occurring peptide may have been deleted and/or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable, have been added to the naturally occurring peptide.

Examples of insulin analogues are Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.

Examples of insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29) (N-tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-glutamyl-des(B30) human insulin (insulin degludec, Tresiba®); B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin; B29-N-(omega-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(omega-carboxyheptadecanoyl) human insulin.

Examples of GLP-1, GLP-1 analogues and GLP-1 receptor agonists are, for example, Lixisenatide ( Lyxumia®, Exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid

peptide which is produced by the salivary glands of the Gila monster), Liraglutide (Victoza®), Semaglutide, Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C, CM-3, GLP-1 Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, Exenatide-XTEN and Glucagon-Xten.

An example of an oligonucleotide is, for example: mipomersen sodium (Kynamro®), a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia.

Examples of DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.

Examples of hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriogonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.

Examples of polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium. An example of a hyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodium hyaluronate.

The term “antibody”, as used herein, refers to an immunoglobulin molecule or an antigen-binding portion thereof. Examples of antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab')<sub>2</sub> fragments, which retain the ability to bind antigens. The antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody. In some embodiments, the antibody has effector function and can fix a

complement. In some embodiments, the antibody has reduced or no ability to bind an Fc receptor. For example, the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region. The term antibody also includes an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins (TBTI) and/or a dual variable region antibody-like binding protein having cross-over binding region orientation (CODV).

The terms "fragment" or "antibody fragment" refer to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen. Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments. Antibody fragments that are useful in the present invention include, for example, Fab fragments, F(ab')<sub>2</sub> fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.

The terms "Complementarity-determining region" or "CDR" refer to short polypeptide sequences within the variable region of both heavy and light chain polypeptides that are primarily responsible for mediating specific antigen recognition. The term "framework region" refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding. Although the framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.

Examples of antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).

Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device. Pharmaceutically acceptable salts are for example acid addition salts and basic salts.

Those of skill in the art will understand that modifications (additions and/or removals) of various components of the APIs, formulations, apparatuses, methods, systems and embodiments described herein may be made without departing from the full scope and spirit of the present invention, which encompass such modifications and any and all equivalents thereof.

DE2017/003 WOPCT

### Claims

1. A medicament delivery device for delivering a liquid medicament comprising:  
a rigid casing containing a deformable medicament container, the deformable medicament container arranged to contain the liquid medicament;  
a pressurized gas cartridge connected to the rigid casing via a gas valve;  
wherein the gas valve is releasable to allow gas flow into the rigid casing to cause an increase in gas pressure in the rigid casing so as to compress the deformable medicament container to displace the liquid medicament.
2. The medicament delivery device of claim 1, further comprising an overflow reservoir connected to the rigid casing via a safety valve, wherein the safety valve is configured to allow gas flow into the overflow reservoir when gas pressure in the rigid casing exceed a predetermined threshold.
3. The medicament delivery device of claim 2, further comprising a flow detection mechanism in the overflow reservoir.
4. The medicament delivery device of claim 3, wherein the flow detection mechanism comprises a rotation member arranged in the overflow reservoir, wherein the rotation member is configured to be rotated by gas flow in the overflow reservoir.
5. The medicament delivery device of claim 4, wherein the rotation member comprises a plurality of vanes.
6. The medicament delivery device of claims 4 or 5, wherein the rotation member is connected to an indicator system.
7. The medicament delivery device of claim 6, wherein the indicator system comprises:  
a transparent window at the housing; and

an indicator member arranged at the rotation member, such that when the rotation member rotates, an outer end of the indicator member moves along the transparent window.

8. The medicament delivery device of claims 4 or 5, wherein the rotation member is connected to an energy generating apparatus.

9. The medicament delivery device of claim 8, wherein the energy generating apparatus comprises a dynamo.

10. The medicament delivery device of claims 8 or 9, further comprising a light source arranged to be powered by the energy generating apparatus.

11. The medicament delivery device of any of the preceding claims, wherein the deformable medicament container is in fluid communication with an outlet, the outlet being connected via a fluid path to a needle injection system.

12. The medicament delivery device of any of the preceding claims, wherein the medicament delivery device is a bolus injector.

13. The injection device of any of the preceding claims, wherein the deformable medicament container contains a liquid medicament.

14. A method of operating a medical delivery device, the medical delivery device comprising a rigid casing containing a deformable medicament container arranged to contain a liquid medicament and a pressurized gas cartridge connected to the rigid casing via a gas valve, the method comprising:

releasing the gas valve to allow gas flow into the rigid casing to cause an increase in gas pressure in the rigid casing so as to compress the deformable medicament container to displace the liquid medicament.

15. The method of claim 14, wherein the medical delivery device further comprises an overflow reservoir connected to the rigid casing via a safety valve, the method further comprising converting motion of gas flow in the overflow reservoir into torque for rotating a rotation member in the overflow reservoir.




Figure 1




Figure 2




Figure 3B




Figure 3A




Figure 4

INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2018/051375

A. CLASSIFICATION OF SUBJECT MATTER  
INV. A61M5/148 A61M5/142  
ADD.  
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED  
Minimum documentation searched (classification system followed by classification symbols)  
A61M  
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y A	EP 1 527 792 A1 (NOVO NORDISK AS [DK]) 4 May 2005 (2005-05-04) paragraph [0074]; figure 17D	1,2 1-3 4-13
X Y A	----- EP 0 098 893 A1 (FERRING ARZNEIMITTEL GMBH [DE]) 25 January 1984 (1984-01-25) page 2 - page 6; figure 1	1 1-3 4-13
Y A	----- EP 0 600 754 A2 (KATO HATSUJO KAISHA LTD [JP]) 8 June 1994 (1994-06-08) column 5 - column 10; figures 1, 7	1-3 4-13
Y A	----- WO 2008/129549 A1 (STEADYMED LTD [IL]; GENOSAR AMIR [US]; GOLDSTEIN JONATHAN [IL]; FLEISH) 30 October 2008 (2008-10-30) page 6 - page 17; figures 1-5	1-3 4-13
	----- -/--	

Further documents are listed in the continuation of Box C.  See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier application or patent but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
"&" document member of the same patent family

Date of the actual completion of the international search  16 February 2018	Date of mailing of the international search report  07/03/2018
---	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer  Preller, D
--	--------------------------------------

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/EP2018/051375

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 2 554 196 A1 (VALERITAS INC [US]) 6 February 2013 (2013-02-06) paragraph [0030] - paragraph [0087]; figures 1-11 -----	1-13

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2018/051375

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 14, 15  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box II.1

Claims Nos.: 14, 15

The subject-matter of claims 14 and 15 comprises matter falling under the provisions of Rule 39.1(iv) PCT Regulations, namely methods for treatment of the human or animal body by therapy. In particular, independent method claim 14 is directed to a "method of operating a medical delivery device " comprising inter alia a step of releasing a gas valve which ultimately causes "to compress the deformable medicament container to displace the liquid medicament ", which involves injecting the medicament from the device and into the human or animal body for therapy; see also claim 11 as well as e.g. description page 7, second complete paragraph: " the increase gas pressure exerts a compressive force on the deformable medicament container 13 so as to displace the liquid medicament contained within through its outlet "; and page 8, first complete paragraph (emphasis added): " The liquid medicament contained within the deformable medicament container 13 is displaced through its outlet, through the fluid path, and to the needle injection system 19 to be injected to an injection site ". Hence, the method comprises the therapeutical method steps of delivering a drug for treatment into the body. This deficiency is also inherent on claim 15 which is dependent on claim 14.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/EP2018/051375
---

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP 1527792	A1	04-05-2005	AT 454177 T	15-01-2010
			CN 1874809 A	06-12-2006
			EP 1527792 A1	04-05-2005
			EP 2343093 A1	13-07-2011
			US 2011137255 A1	09-06-2011
			ZA 200602911 B	25-07-2007
EP 0098893	A1	25-01-1984	AT 30116 T	15-10-1987
			DE 3277436 D1	12-11-1987
			EP 0098893 A1	25-01-1984
EP 0600754	A2	08-06-1994	NONE	
WO 2008129549	A1	30-10-2008	EP 2144647 A1	20-01-2010
			ES 2395775 T3	15-02-2013
			US 2010087778 A1	08-04-2010
			WO 2008129549 A1	30-10-2008
EP 2554196	A1	06-02-2013	AU 2002241567 A1	24-07-2002
			CA 2430590 A1	18-07-2002
			EP 1412017 A2	28-04-2004
			EP 2554196 A1	06-02-2013
			EP 2578252 A1	10-04-2013
			ES 2574917 T3	23-06-2016
			US 2002169416 A1	14-11-2002
			US 2006189939 A1	24-08-2006
			US 2009093763 A1	09-04-2009
			US 2013138042 A1	30-05-2013
			US 2015165115 A1	18-06-2015
			US 2017189610 A1	06-07-2017
			WO 02055128 A2	18-07-2002